| Bioactivity | VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1)/VEGFR2 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model[1]. |
| Sequence | Lys-Ala-Trp-Ala-Glu-Cys-Arg-Pro-Pro-Asp-Glu-Gly-Leu-Cys (Disulfide bridge: Cys6-Cys14) |
| Shortening | KAWAECRPPDEGLC (Disulfide bridge: Cys6-Cys14) |
| Formula | C67H101N19O21S2 |
| Molar Mass | 1572.76 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zanjanchi P, et al. Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity. J Nanobiotechnology. 2022 Jan 4;20(1):7. |